Need a report that reflects how COVID-19 has impacted this market and its growth?
The bone cancer treatment market was valued at approximately USD 1,158 million in 2020, and it is expected to reach USD 1,547 million by 2026, witnessing a CAGR of 4.9% during the forecast period.
During the early stages of COVID-19, there was a significant reduction in the number of cases treated at the musculoskeletal oncology departments, which have affected the number of surgical volumes. The massive reduction in musculoskeletal oncology services may have drastic consequences for affected patients and the overall market growth. However, several precautionary guidelines were issued by the respective government authorities to initiate the delayed or postponed bone cancer treatments, enabling patients to acquire safe access to treatment during the COVID-19 pandemic.
Certain factors driving the market growth include the increasing global burden of bone cancer and government initiatives for bone cancer awareness. The incidence of bone cancer is on a steady rise and needs to be addressed at the earliest to reduce the burden of bone sarcoma across the world.
According to estimates by the American Society of Clinical Oncology, the United States is estimated to witness 3,610 new cases of bone cancer and an expected 2,060 deaths due to bone cancer in 2021. The chemotherapeutic drugs approved for the treatment of bone cancer do not have an effective treatment regime, as it always varies according to the prevailing conditions and the way the patient’s body responds to the drug. Hence, the associated side effects, risks, and limitations of the treatment are limiting the growth of the bone cancer treatment drug market.
Scope of the Report
As per the scope, bone cancer refers to a malignant tumor that arises from cells of bones of the body. It is also known as primary bone cancer, as it originates in the bones. Secondary bone cancer refers to a tumor that has spread to the bone area but originated elsewhere. In this report, a detailed analysis of the bone cancer treatment market is presented, with specific attention on primary bone cancer. The bone cancer treatment market is segmented by bone cancer type (primary bone cancer [osteosarcoma, chondrosarcoma, Ewing tumor, and other bone cancer types] and secondary bone cancer [metastatic bone cancer]), treatment type (chemotherapy, targeted therapy, radiation therapy, surgery, and other treatments), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the market size and forecasts in value (USD million) for the above segments.
|Bone Cancer Type|
|Secondary Bone Cancer (Metastatic Bone Cancer)|
Key Market Trends
Osteosarcoma is Expected to Hold the Largest Share in the Market Over the Forecast Period
The COVID-19 pandemic has disrupted surgical procedures, chemotherapy timings, and frequent hospital visits. In addition, a radical change in the osteosarcoma surgical plan was also observed due to the COVID-19 pandemic. In the bone cancer type segment of the market, among all primary bone cancers, osteosarcoma is expected to have the largest market size over the forecast period.
Osteosarcoma is the most common type of cancer affecting the bones, and it mostly occurs in children and young adults. Based on the cells, osteosarcoma is classified as high-, intermediate-, and low-grade. According to the American Cancer Society, 2019, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States every year, with about half of these occurring in children and teenagers.
Research on osteosarcoma is done at various medical centers, university hospitals, and other institutions across the world. Many advancements have taken place in the treatment of osteosarcoma in the past few decades. Osteosarcoma can be treated by surgery, radiation therapy, chemotherapy, targeted therapy drugs, etc.
Thus, research related to the bone cancer treatment market is increasing, owing to the high prevalence of osteosarcoma globally.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to do the Same in the Forecast Period
In North America, the COVID-19 pandemic largely affected the US region, which led to disruptions in many surgical procedures. However, currently, the surgical procedures are being carried out with precautionary measures, which will further lead to steady growth of the market.
North America currently dominates the bone cancer treatment market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that, currently, in the region, mainly in the United States, many clinical trials are underway for bone cancer therapies. Some studies are testing new chemo drugs. Researchers are also looking for new ways to use the existing approved drug portfolio. For instance, doctors are studying whether adding a bisphosphonate called zoledronic acid (Zometa) to the bone cement, which is used in filling the space left after removing a giant cell tumor, may decrease the chances of that tumor returning in that place.
To understand geography trends, Download Sample Report
The bone cancer treatment market is highly competitive and consists of a considerable number of significant players. All of the existing players in the market are either legacy suppliers of treatment options, like chemotherapy and radiation therapy, or are concentrating on clinical trials for novel bone cancer approaches, including targeted therapy and immunotherapy. Companies like Bayer AG, Amgen, Novartis AG, and Pfizer Inc., among others, are expected to hold substantial shares in the bone cancer treatment market.
In October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc.
In February 2020, Count Me In, a non-profit research initiative, launched the Osteosarcoma Project, a patient-partnered effort that enables people in the United States and Canada who have been affected by osteosarcoma to accelerate research.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Bone Cancer
4.2.2 Increasing Government Initiatives for Bone Cancer Awareness
4.3 Market Restraints
4.3.1 Unavailability of Effective Treatment and Side Effects
4.3.2 High Cost of Cancer Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size in Value)
5.1 Bone Cancer Type
5.1.1 Primary Bone Cancer
126.96.36.199 Ewing Tumor
188.8.131.52 Other Bone Cancer Types
5.1.2 Secondary Bone Cancer (Metastatic Bone Cancer)
5.2 Treatment Type
184.108.40.206 Other Chemotherapies
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.5 Other Treatments
5.3.1 North America
220.127.116.11 United States (By Cancer Type and Treatment Type)
18.104.22.168 Canada (By Cancer Type and Treatment Type)
22.214.171.124 Mexico (By Cancer Type and Treatment Type)
126.96.36.199 Germany (By Cancer Type and Treatment Type)
188.8.131.52 United Kingdom (By Cancer Type and Treatment Type)
184.108.40.206 France (By Cancer Type and Treatment Type)
220.127.116.11 Italy (By Cancer Type and Treatment Type)
18.104.22.168 Spain (By Cancer Type and Treatment Type)
22.214.171.124 Rest of Europe (By Cancer Type and Treatment Type)
126.96.36.199 China (By Cancer Type and Treatment Type)
188.8.131.52 Japan (By Cancer Type and Treatment Type)
184.108.40.206 India (By Cancer Type and Treatment Type)
220.127.116.11 Australia (By Cancer Type and Treatment Type)
18.104.22.168 South Korea (By Cancer Type and Treatment Type)
22.214.171.124 Rest of Asia-Pacific (By Cancer Type and Treatment Type)
5.3.4 Middle-East and Africa
126.96.36.199 GCC (By Cancer Type and Treatment Type)
188.8.131.52 South Africa (By Cancer Type and Treatment Type)
184.108.40.206 Rest of Middle-East and Africa (By Cancer Type and Treatment Type)
5.3.5 South America
220.127.116.11 Brazil (By Cancer Type and Treatment Type)
18.104.22.168 Argentina (By Cancer Type and Treatment Type)
22.214.171.124 Rest of South America (By Cancer Type and Treatment Type)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.3 Bayer AG
6.1.4 Hikma Pharmaceuticals
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Recordati Group
6.1.9 Takeda Pharmaceutical Company
6.1.11 Eli Lilly and Company
6.1.13 Spectrum Pharmaceuticals Inc.
6.1.14 IceCure Medical
6.1.15 Isofol Medical AB
6.1.17 Daiichi Sankyo Company
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Bone Cancer Treatment Market market is studied from 2018 - 2026.
What is the growth rate of Global Bone Cancer Treatment Market?
The Global Bone Cancer Treatment Market is growing at a CAGR of 4.9% over the next 5 years.
Which region has highest growth rate in Global Bone Cancer Treatment Market?
North America is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Bone Cancer Treatment Market?
North America holds highest share in 2020.
Who are the key players in Global Bone Cancer Treatment Market?
- Bayer AG
- Pfizer Inc.
- Novartis International AG
- Johnson and Johnson
Are the major companies operating in Global Bone Cancer Treatment Market.